TRACON Enters Strategic Collaboration with Janssen

San Diego – October 6, 2016 – Cooley advised TRACON Pharmaceuticals on its strategic licensing collaboration with Janssen Pharmaceutical for two novel oncology assets and on its $5 million equity investment from Johnson & Johnson Innovation – JJDC.

The transaction grants TRACON the rights to develop two Janssen oncology programs: TRC253, a novel small molecule high affinity competitive inhibitor of wild type androgen receptor (AR) and multiple AR mutations that confer drug resistance, intended for the treatment of men with prostate cancer; and TRC694, a novel, potent, orally bioavailable inhibitor of NF-kB inducing kinase, intended for the treatment of patients with hematologic malignancies including myeloma.

TRACON is a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet ageā€related macular degeneration and fibrotic diseases. Janssen is a pharmaceutical company headquartered in Belgium.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law. 

Cooley has 900 lawyers across 12 offices in the United States, China and Europe.

Related Contacts
Kay Chandler Partner, San Diego
Jane Adams Partner, San Diego
Sean Clayton Partner, San Diego
Tanisha A. James Partner, New York
Andrew Harline Associate, Shanghai